Skip to content

Fighting to Preserve the Benefits of the 340B Program

  • About Us
  • Contact Us
Top Bar Menu
Facebook page opens in new windowTwitter page opens in new windowLinkedin page opens in new windowMail page opens in new window
RWC-340B
Ryan White Clinics for 340B Access
RWC-340B
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
    • Webinars
  • News
Search:
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
    • Webinars
  • News

Johnson Johnson Logo

Johnson & Johnson is the 16th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies

Congress, Drug Pricing, News, RWC-340BBy Amber TynanMarch 23, 2022

By letter dated March 21, 2021, Johnson & Johnson (J&J) announced that, effective May 2, 2022, it will no longer honor bill-to/ship-to orders for contract pharmacy arrangements with hospitals unless…

Gilead

RWC-340B Sends Gilead Letter Requesting Exceptions for MAP/PAP Policies

Drug Pricing, News, RWC-340BBy Amber TynanMarch 17, 2022

Please see the attached letter to Mr. Charles Clapton, VP of Federal Governmental Affairs with Gilead from RWC-340B President, Shannon Stephenson on behalf of RWC-340B requesting exceptions to MAP/PAP Policies. Should you…

bill 5665872 1920

Pfizer and GSK Announce Policies to Restrict Access to 340B Drugs at Contract Pharmacies; Novo Nordisk Modifies Its Policy

News, RWC-340BBy Amber TynanFebruary 16, 2022

Pfizer and GlaxoSmithKline (“GSK”) are the 13th and 14th manufacturers, respectively, to restrict 340B pricing on drugs shipped to contract pharmacies.  Novo Nordisk, which previously restricted access to 340B pricing to one…

Joe Biden

POTUS Pledges to Enforce 340B Program

News, RWC-340B, White HouseBy Amber TynanFebruary 16, 2022

President Joe Biden yesterday during a major speech on drug pricing reform applauded U.S. Rep. Abigail Spanberger (D-Va.) for being “relentless in making sure” that the 340B statute “is actually…

Hiring

RWC-340B Seeking Managing Director

NewsBy Amber TynanJanuary 26, 2022

Summary The Managing Director of the Ryan White Clinics for 340B Access Coalition (RWC-340B) reports to the Executive Director of United Partners for Human Services (UPHS), the managed service organization…

Spanberger

Spanberger to HHS: Hold Drug Companies Accountable for Breaking the Law, Crack Down on Illegal Price Hikes

Drug Pricing, HHS, NewsBy Amber TynanJanuary 26, 2022

In response to a rash of reckless decisions by pharmaceutical companies, U.S. Representative Abigail Spanberger is leading a bipartisan effort to protect the 340B Drug Pricing Program and prevent additional…

thought catalog kkysaOcVE94 unsplash

BMS is the 12th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies; Permits Designation of One Contract Pharmacy for Three Cancer Drugs

Drug Pricing, NewsBy Andrea JeriaJanuary 20, 2022

By email dated January 14, 2022, Bristol Myers Squibb (BMS) announced that, effective March 1, 2022, it will implement a new 340B contract pharmacy policy impacting two drug categories: non-immunomodulatory…

eye g4f3076735 1920

Second Sight Updates 340B ESP Terms of Use

Drug Pricing, NewsBy Andrea JeriaJanuary 6, 2022

In October 2021, Second Sight, the owner of 340B ESP, updated the Terms of Use (TOU) that covered entities must agree to when registering for the 340B ESP platform.  There…

volodymyr hryshchenko m1Hq4ibP9rc unsplash

New AbbVie and Lilly Contract Pharmacy Policies

Drug Pricing, HHS, HRSA, NewsBy Andrea JeriaJanuary 6, 2022

AbbVie is the 11th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies By letter dated December 29, 2021, AbbVie announced that, effective February 1, 2022, it will implement…

glsun guilin WNX6uk 1LV4 unsplash

UCB Latest Manufacturer to Announce Restrictive Contract Pharmacy Policy; HRSA Issues Statement Regarding Manufacturer Lawsuits

Drug Pricing, HHS, HRSA, NewsBy Andrea JeriaNovember 23, 2021

By letter dated November 22, 2021, drug manufacturer UCB, Inc. notified covered entities that it is “altering its 340B policy” and will no longer honor contract pharmacy arrangements, effective December…

→12345…
678910111213
14→
                                                                            © 2021 Ryan White Clinics for 340B Access. RWC-340B is a 501(c)(4) non-profit corporation.
Go to Top
Translate »
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset